<DOC>
	<DOCNO>NCT01781442</DOCNO>
	<brief_summary>This post marketing surveillance determines safety profile product Filipinos . This FDA requirement registration .</brief_summary>
	<brief_title>A Post Marketing Surveillance As Required By Philippine Food And Drug Administration</brief_title>
	<detailed_description>The Philippine Food Drug Administration require post marketing surveillance study conduct nationwide enroll approximately 3,000 study patient . In case 3,000 patient meet , total sample size reduce 10 % volume drug use first year market . Final sample size determine one year marketing authorization . The decision use Torisel must joint decision make subject investigator . The investigator must discuss product information subject per usual practice .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Subjects include post marketing surveillance study must consistent approve label indication Torisel Philippines . As per approve label indication , patient diagnose advanced renal cell carcinoma one eligible participate study . The decision prescribe Torisel necessarily precede independent decision enroll patient study . Evidence personally sign date informed consent document indicate subject ( legally acceptable representative ) inform pertinent aspect study . Subjects condition contraindicate Torisel base approve local product document Philippines exclude study . This condition include : Patients bilirubin &gt; 1.5 x ULN .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Metastatic Renal Cell Carcinoma</keyword>
</DOC>